Modality
Fusion Protein
MOA
IL-17i
Target
C5
Pathway
PD-1/PD-L1
BCCGADMD
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ Jul 2027
Phase 1Current
NCT03807860
293 pts·DMD
2019-09→2025-11·Recruiting
NCT05780096
2,426 pts·GA
2018-06→2027-07·Terminated
2,719 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-135mo agoInterim· DMD
2027-07-261.3y awayInterim· GA
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Termina…
P1
Recruit…
Catalysts
Interim
2025-11-13 · 5mo ago
DMD
Interim
2027-07-26 · 1.3y away
GA
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03807860 | Phase 1 | DMD | Recruiting | 293 | OS |
| NCT05780096 | Phase 1 | GA | Terminated | 2426 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ARG-1250 | Argenx | Phase 2 | C5 |